Cargando…
Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. OBJECTIVE: This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lympho...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877659/ https://www.ncbi.nlm.nih.gov/pubmed/27208567 http://dx.doi.org/10.1016/j.bjhh.2016.02.006 |
_version_ | 1782433421137543168 |
---|---|
author | Fonseca-Hial, Ana Marcela Rojas Parisio, Katya Oliveira, Jose Salvador Rodrigues |
author_facet | Fonseca-Hial, Ana Marcela Rojas Parisio, Katya Oliveira, Jose Salvador Rodrigues |
author_sort | Fonseca-Hial, Ana Marcela Rojas |
collection | PubMed |
description | BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. OBJECTIVE: This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. METHODS: This article reports on 29 adult patients submitted to allogeneic transplantations from 1997 to 2010. RESULTS: Most had follicular non-Hodgkin lymphoma (n = 14) or chronic lymphocytic leukemia (n = 12). The median age was 44 years (range: 24–53 years) and 65% of patients were male. Only 21% had had access to rituximab and 45% to fludarabine. All had advanced disease (stage IV) with partial response or stable disease. Most underwent myeloablative conditioning n = 17 – 59%). In this scenario, refractory disease was observed in seven (24%) patients, the 100-day mortality rate was 17% (n = 5) and relapse occurred in four patients (18%). The main cause of death throughout the follow up was refractory disease in six of the 12 patients who died. Moderate and severe chronic graft-versus-host disease was frequent; about 41% of 24 patients analyzed. The overall survival rates and disease free survival at 42 months were 56.7% and 45.4%, respectively. According to Kaplan–Meyer analysis, the median time from diagnosis to transplant predicted the overall survival; however age, gender and conditioning regimen did not predict the prognosis. It was impossible to reach other conclusions because of the small sample size in this study. CONCLUSIONS: The role of allogeneic transplantations should be re-evaluated in the era of targeted therapy. |
format | Online Article Text |
id | pubmed-4877659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Sociedade Brasileira de Hematologia e Hemoterapia |
record_format | MEDLINE/PubMed |
spelling | pubmed-48776592016-06-09 Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders Fonseca-Hial, Ana Marcela Rojas Parisio, Katya Oliveira, Jose Salvador Rodrigues Rev Bras Hematol Hemoter Original Article BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. OBJECTIVE: This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. METHODS: This article reports on 29 adult patients submitted to allogeneic transplantations from 1997 to 2010. RESULTS: Most had follicular non-Hodgkin lymphoma (n = 14) or chronic lymphocytic leukemia (n = 12). The median age was 44 years (range: 24–53 years) and 65% of patients were male. Only 21% had had access to rituximab and 45% to fludarabine. All had advanced disease (stage IV) with partial response or stable disease. Most underwent myeloablative conditioning n = 17 – 59%). In this scenario, refractory disease was observed in seven (24%) patients, the 100-day mortality rate was 17% (n = 5) and relapse occurred in four patients (18%). The main cause of death throughout the follow up was refractory disease in six of the 12 patients who died. Moderate and severe chronic graft-versus-host disease was frequent; about 41% of 24 patients analyzed. The overall survival rates and disease free survival at 42 months were 56.7% and 45.4%, respectively. According to Kaplan–Meyer analysis, the median time from diagnosis to transplant predicted the overall survival; however age, gender and conditioning regimen did not predict the prognosis. It was impossible to reach other conclusions because of the small sample size in this study. CONCLUSIONS: The role of allogeneic transplantations should be re-evaluated in the era of targeted therapy. Sociedade Brasileira de Hematologia e Hemoterapia 2016 2016-03-19 /pmc/articles/PMC4877659/ /pubmed/27208567 http://dx.doi.org/10.1016/j.bjhh.2016.02.006 Text en © 2016 Associaç˜ao Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Fonseca-Hial, Ana Marcela Rojas Parisio, Katya Oliveira, Jose Salvador Rodrigues Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
title | Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
title_full | Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
title_fullStr | Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
title_full_unstemmed | Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
title_short | Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
title_sort | allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877659/ https://www.ncbi.nlm.nih.gov/pubmed/27208567 http://dx.doi.org/10.1016/j.bjhh.2016.02.006 |
work_keys_str_mv | AT fonsecahialanamarcelarojas allogeneichematopoieticstemcelltransplantationinpatientswithadvancedindolentlymphoproliferativedisorders AT parisiokatya allogeneichematopoieticstemcelltransplantationinpatientswithadvancedindolentlymphoproliferativedisorders AT oliveirajosesalvadorrodrigues allogeneichematopoieticstemcelltransplantationinpatientswithadvancedindolentlymphoproliferativedisorders |